Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...
Altimmune, Inc. (ALT) today released mixed results from its phase 2b IMPACT trial, using its peptide-based GLP-1/glucagon receptor agonist pemvidutide for the treatment of patients with metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results